Immunocore Holdings plc Investment Income, Interest
Immunocore Holdings plc (IMCR) reported Investment Income, Interest of $3.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- Immunocore Holdings plc investment income, interest for the quarter ending 2026-06-30 was $3.58M, a 16.13% decline year-over-year.
- Immunocore Holdings plc investment income, interest for the quarter ending 2026-03-31 was $3.42M, a 18.15% decline year-over-year.
- Immunocore Holdings plc investment income, interest for the quarter ending 2025-12-31 was $3.91M, a 24.49% decline year-over-year.
- Immunocore Holdings plc investment income, interest for the quarter ending 2025-09-30 was $4.12M, a 30.82% decline year-over-year.
- Immunocore Holdings plc investment income, interest for fiscal 2025 was $16.48M, a 35.69% decline from fiscal 2024.
- Immunocore Holdings plc investment income, interest for fiscal 2024 was $25.62M, a 42.43% increase from fiscal 2023.
- Immunocore Holdings plc investment income, interest for fiscal 2023 was $17.99M, a 378.86% increase from fiscal 2022.
- Immunocore Holdings plc investment income, interest for fiscal 2022 was $3.76M, a 5678.46% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.58M 10-Q · filed 2026-08-06 | $7.00M 10-Q · filed 2026-08-06 | $10.91M derived: sum of 3 quarters · filed 2026-08-06 | $15.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.42M 10-Q · filed 2026-05-06 | $7.32M derived: sum of 2 quarters · filed 2026-05-06 | $11.45M derived: sum of 3 quarters · filed 2026-05-06 | $15.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.03M derived: sum of 2 quarters · filed 2026-02-25 | $12.30M derived: sum of 3 quarters · filed 2026-08-06 | $16.48M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.12M 10-Q · filed 2025-11-06 | $8.39M derived: sum of 2 quarters · filed 2026-08-06 | $12.57M 10-Q · filed 2025-11-06 | $17.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.27M 10-Q · filed 2026-08-06 | $8.45M 10-Q · filed 2026-08-06 | $13.62M derived: sum of 3 quarters · filed 2026-08-06 | $19.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.18M 10-Q · filed 2026-05-06 | $9.35M derived: sum of 2 quarters · filed 2026-05-06 | $15.31M derived: sum of 3 quarters · filed 2026-05-06 | $21.55M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.13M derived: sum of 2 quarters · filed 2026-02-25 | $17.37M derived: sum of 3 quarters · filed 2026-02-25 | $25.62M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.96M 10-Q · filed 2025-11-06 | $12.20M derived: sum of 2 quarters · filed 2025-11-06 | $20.45M 10-Q · filed 2025-11-06 | $25.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $6.24M 10-Q · filed 2025-08-07 | $14.48M 10-Q · filed 2025-08-07 | $19.93M derived: sum of 3 quarters · filed 2026-02-25 | $25.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $8.25M 10-Q · filed 2025-05-07 | $13.69M derived: sum of 2 quarters · filed 2026-02-25 | $18.83M derived: sum of 3 quarters · filed 2026-02-25 | $23.11M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.58M derived: sum of 2 quarters · filed 2026-02-25 | $14.86M derived: sum of 3 quarters · filed 2026-02-25 | $17.99M 10-K · filed 2026-02-25 |
| 2023-09-30 | $5.14M 10-Q · filed 2024-11-06 | $9.42M derived: sum of 2 quarters · filed 2024-11-06 | $12.55M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $4.28M 10-Q · filed 2024-08-08 | $7.41M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $3.13M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $3.76M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $65.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |